Evans Syndrome
New Evans syndrome research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), sirolimus had the strongest new treatment evidence for relapsed/refractory Evans syndrome. Studies also kept highlighting underlying immune disorders and groups that may have higher risks. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Sirolimus for refractory disease. Evidence strengthened from cohorts to an adult clinical trial.
- Other treatment options. Multiple nonstandard approaches appeared, with mixed evidence strength.
- Complex clinical settings. Reports repeatedly tied Evans syndrome to broader illnesses and triggers.
- Long-term risks in children. Cohorts linked Evans syndrome to relapse and later lupus/APS.
- Immune causes and testing. More studies connected Evans syndrome to inborn immune disorders.
New
September 2026
- Genetic immune disorders. In children, Evans syndrome was more common with confirmed genetic immune disorders.
- Low counts and swelling. Multiple low blood counts and enlarged spleen or lymph nodes were more common with genetic findings.
- TB-related flare. One severe case improved after tuberculosis treatment plus steroids.
- Case-by-case treatment. Single case reports described improvement with avatrombopag or with IVIG plus steroids.
August 2026
- Sirolimus in children. Sirolimus helped in children, but key details were missing.
- After transplant treatment. Steroids and IVIg did not work for everyone after transplant.
- Immune conditions linked. Some reports linked Evans syndrome to rare immune conditions.
July 2026
- Rapid blood count rise. A combined immune treatment was linked to fast blood count recovery.
- Infection risk. Infections were the most reported side effect and were treated.
- Platelet-boosting drug. One cancer-linked case improved after a platelet-stimulating medicine.
- Childhood relapse risk. In children, Evans syndrome was linked to relapse and later autoimmune disease.
June 2026
- Sirolimus results. Many adults improved with sirolimus in a clinical trial.
- Side effect pattern. Side effects were usually mild and went away.
- Efgartigimod case. One person improved, but this does not show typical results.
- ANA follow-up risk. Ongoing positive ANA in children was linked to later lupus.
May 2026
- Late after transplant. Evans-like immune blood count problems were reported months to years after transplant and often required more than one treatment step.
- Infection and clot risks. In transplant settings, infections and blood clots were frequently reported alongside Evans-like blood problems.
- Platelet recovery in leukemia case. One leukemia case report described platelet recovery after romiplostim and zanubrutinib following earlier treatments.
- Surgery planning. One surgery case report described stable blood counts with coordinated care around the time of the operation.
April 2026
- More severe lupus flares. In systemic lupus erythematosus (SLE), Evans syndrome was reported more often during more severe lupus flares.
- Kidney and nervous system involvement. In SLE cases with Evans syndrome, kidney and nervous system involvement were reported more often.
- Severe infections. Severe infections were reported more often in SLE cases with Evans syndrome.
- CD19 CAR T-cell case report. One single-patient report described improved hemoglobin and platelets after CD19 CAR T-cell therapy in refractory SLE-associated Evans syndrome.
March 2026
- Fostamatinib in refractory disease. In routine-care reports, fostamatinib was linked with durable responses in some people with refractory Evans syndrome, but side effects were also reported.
- Immune markers and response. Small early studies reported possible links between immune markers and treatment response, but the signals were preliminary.
- Children: shifting blood counts. Follow-up in children showed Evans syndrome can change over time and may affect more than one blood cell line.
- Serious infection example. One case report described a serious Listeria infection in an immunosuppressed patient who later recovered.
February 2026
- Clot risk has multiple contributors. This update described blood clot risk in Evans syndrome as coming from several overlapping factors rather than a single cause.
January 2026
- Inborn immune causes. Inborn immune problems were often found in Evans syndrome.
- Lab immune signals. Low antibodies and fewer naive T cells linked to immune causes.
- High-risk settings. After transplant or with thymoma, relapses and complications were frequent.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Evans syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).